Temozolomide

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Glioblastoma, Glioma, Malignant Brain Tumors

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
US
  • Anaplastic astrocytoma, adjuvant for newly diagnosed disease and for refractory diseaseFDA label
  • Anaplastic Astrocytoma TEMODAR is indicated for the: adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma; treatment of adults with refractory anaplastic astrocytoma.FDA label
Product first approved 2005Outside this platform's coverage
EU
  • Temodal hard capsules is indicated for the treatment of: adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment; children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Product first approved 1999EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (56)
Glioblastoma
NCT07935889 · Mayo Clinic
2026-11-13 – 2035-11-30 · Glioblastoma, IDH-Wildtype
What this study did
NCT06477939 · Institut de cancérologie Strasbourg Europe
2025-01-01 – 2032-12-31 · Glioblastoma
What this study did
NCT05095376 · NRG Oncology
2022-03-28 – 2031-02-12 · Glioblastoma, Gliosarcoma
What this study did
NCT05439278 · Severance Hospital
2025-02-01 – 2030-12-31 · Glioblastoma
What this study did
NCT05271240 · Northwell Health
2022-04-27 – 2028-04-01 · Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant, GBM, Brain Cancer, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Adult
What this study did
NCT03663725 · Centre Oscar Lambret
2019-03-13 – 2027-06 · Glioblastoma
What this study did
NCT05600491 · Sun Yat-sen University
2015-11-08 – 2025-12-01 · Anaplastic Oligoastrocytoma, Glioblastoma
What this study did
NCT05326464 · University of Texas Southwestern Medical Center
2022-10-07 – 2025-10-31 · Glioblastoma
What this study did
NCT02761070 · Kyorin University
2016-07-11 – 2025-04-17 · Glioblastoma, Recurrence, Progression
What this study did
NCT03243461 · University of Göttingen
2018-07-17 – 2023-12-31 · Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV, Anaplastic Astrocytoma WHO Grade III, Diffuse Intrinsic Pontine Glioma, Gliomatosis Cerebri
What this study did
NCT04829097 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2020-11-01 – 2023-11-01 · Glioblastoma
What this study did
NCT03345095 · European Organisation for Research and Treatment of Cancer - EORTC
2018-07-26 – 2023-06-30 · Newly Diagnosed Glioblastoma
What this study did
NCT03633552 · Mashhad University of Medical Sciences
2018-03-03 – 2021-04-03 · Glioblastoma Multiforme of Brain, Anaplastic Astrocytoma of Brain
What this study did
NCT03419403 · AbbVie
2018-07-30 – 2020-03-03 · Glioblastoma Multiforme
What this study did
NCT01765088 · Sun Yat-sen University
2012-09 – 2019-12 · Anaplastic Oligoastrocytoma, Anaplastic Astrocytoma, Glioblastoma
What this study did
NCT01830101 · AHS Cancer Control Alberta
2014-02 – 2017-11 · Recurrent Glioblastoma
What this study did
NCT01149109 · University Hospital, Bonn
2010-10 – 2017-04-06 · Glioblastoma
What this study did
NCT00304031 · Radiation Therapy Oncology Group
2006-01 – 2016-12 · Brain and Central Nervous System Tumors
What this study did
NCT01480479 · Celldex Therapeutics
2011-11 – 2016-11 · Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component
What this study did
NCT00482677 · Canadian Cancer Trials Group
2007-11-14 – 2016-08-10 · Brain and Central Nervous System Tumors
What this study did
NCT00615186 · Bradmer Pharmaceuticals Inc.
2008-06 – 2013-12 · Glioblastoma Multiforme
What this study did
NCT00807027 · GC Cell Corporation
2008-12-05 – 2012-10 · Glioblastoma
What this study did
NCT01502241 · Heidelberg University
2005-01 – 2011-11 · Glioblastoma, Anaplastic Astrocytoma
What this study did
NCT00820963 · Centre Leon Berard
2006-07 – 2011-05 · Brain and Central Nervous System Tumors
What this study did
NCT01364064 · King Faisal Specialist Hospital & Research Center
2007-01 – 2008-06 · Glioblastoma
What this study did
NCT00068952 · Pfizer
2003-08 – 2006-03 · Glioblastoma
What this study did
NCT00335075 · Merck Sharp & Dohme LLC
2005-03-02 – 2006-02-23 · Glioblastoma, Astrocytoma
What this study did
Glioma
NCT00887146 · Alliance for Clinical Trials in Oncology
2009-09 – 2029-10-31 · Brain and Central Nervous System Tumors
What this study did
NCT06330337 · The Third Affiliated hospital of Zhejiang Chinese Medical University
2024-04-01 – 2027-12-31 · Glioma
What this study did
NCT00978458 · Eastern Cooperative Oncology Group
2009-11-17 – 2026-12-31 · Brain and Central Nervous System Tumors, Neurotoxicity
What this study did
NCT01649830 · Sun Yat-sen University
2012-07 – 2026-08 · Astrocytoma, Oligodendroglioma, Oligodendroastrocytoma
What this study did
NCT00897377 · Sun Yat-sen University
started 2007-12 · Astrocytomas, Oligodendrogliomas, Oligoastrocytoma
What this study did
NCT00052455 · Institute of Cancer Research, United Kingdom
2002-10 – 2010-09 · Brain and Central Nervous System Tumors
What this study did
Malignant Brain Tumors
NCT00392886 · Children's Hospital Los Angeles
2004-03 – 2010-12 · Brain and Central Nervous System Tumors
What this study did
Other / comorbidity
NCT07591493 · Gustave Roussy, Cancer Campus, Grand Paris
2026-09 – 2035-06 · Pancreatic Neuroendocrine Tumors (pNET), Pancreatic Neuroendocrine Tumors
What this study did
NCT04221035 · Gustave Roussy, Cancer Campus, Grand Paris
2019-11-05 – 2032-11 · High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
What this study did
NCT07910760 · Tata Memorial Hospital
2026-10-11 – 2031-10-11 · Gastroenteropancreatic Neuroendocrine Tumors
What this study did
NCT06172296 · National Cancer Institute (NCI)
2024-04-19 – 2029-12-31 · Ganglioneuroblastoma, Nodular, Neuroblastoma
What this study did
NCT07375563 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2025-11-19 – 2028-11-19 · Neuroblastoma (NB), Ganglioneuroblastoma
What this study did
NCT06490536 · IFOM ETS - The AIRC Institute of Molecular Oncology
2024-10-22 – 2028-09-01 · Colon Cancer Stage II, Colon Cancer Stage III
What this study did
NCT04164199 · BeOne Medicines
2019-12-19 – 2026-05-23 · Advanced Malignancies
What this study did
NCT02313389 · Assistance Publique - Hôpitaux de Paris
2015-09 – 2023-04 · Primary Central Nervous System Lymphoma
What this study did
NCT03778541 · Chinese Academy of Medical Sciences
2018-12-03 – 2022-12-03 · Brain Metastases, Chemotherapy, Radiotherapy
What this study did
NCT03495921 · Gradalis, Inc.
2018-08-21 – 2022-01-20 · Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
What this study did
Phase 2/3 (14)
Glioblastoma
NCT07605364 · Alliance for Clinical Trials in Oncology
2026-06-10 – 2031-01-05 · Advanced Glioblastoma
What this study did
NCT04105374 · NRG Oncology
2020-01-31 – 2030-11-30 · Anaplastic Astrocytoma, Glioblastoma, Oligodendroglioma, Supratentorial Glioblastoma
What this study did
NCT05685004 · TVAX Biomedical
2023-12-27 – 2030-11 · Glioblastoma Multiforme of Brain
What this study did
NCT07873996 · Beijing Tiantan Hospital
2026-10-15 – 2030-10-15 · Newly Diagnosed Glioblastoma, IDH-wildtype
What this study did
NCT02152982 · National Cancer Institute (NCI)
2014-12-15 – 2026-12-26 · Glioblastoma, Gliosarcoma
What this study did
NCT03008148 · Johnpro Biotech, Inc.
2018-10-11 – 2025-04 · Glioblastoma
What this study did
Glioma
NCT04316039 · West China Hospital
2018-04-10 – 2028-12-31 · Low-grade Glioma
What this study did
NCT01236560 · National Cancer Institute (NCI)
2011-01-26 – 2023-12-31 · Brain Stem Glioma, Cerebral Astrocytoma, Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma, Childhood Spinal Cord Neoplasm
What this study did
Other / comorbidity
NCT07549321 · Renaissance Pharma Ltd.
2026-03-30 – 2031-03 · High-Risk Neuroblastoma
What this study did
NCT05432791 · National Cancer Institute (NCI)
2023-03-30 – 2027-01-30 · Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
What this study did
NCT04244708 · Peking Union Medical College Hospital
2020-02-10 – 2023-12-01 · Pituitary Adenomas
What this study did
NCT03732482 · Taizhou Hospital
2019-03-01 – 2022-05-30 · Non Small Cell Lung Cancer Metastatic
What this study did
NCT02772107 · Chinese PLA General Hospital
2015-12 – 2018-01 · Extensive-stage Small Cell Lung Cancer
What this study did
NCT00749723 · University Hospital, Bonn
2006-02-01 – 2016-01-31 · Recurrent Brain Tumors, Supratentorial PNETs, Medulloblastomas, Ependymomas
What this study did
Phase 2 (420)
Glioblastoma
NCT07708961 · Mayo Clinic
2026-08-28 – 2036-08-31 · Glioblastoma, IDH-Wildtype
What this study did
NCT05843253 · Nationwide Children's Hospital
2024-08-22 – 2034-08-28 · High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Hemispheric Glioma, H3 G34-Mutant
What this study did
NCT04765514 · AHS Cancer Control Alberta
2022-07-27 – 2032-06 · Glioblastoma Multiforme
What this study did
NCT06805305 · Diakonos Oncology Corporation
2025-03-17 – 2032-03 · Glioblastoma (GBM)
What this study did
NCT06991101 · Baptist Health South Florida
2025-12-03 – 2030-12 · Glioblastoma, Brain Cancer, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma
What this study did
NCT04752813 · BPGbio
2022-08-22 – 2030-08-26 · Glioblastoma, Glioblastoma Multiforme
What this study did
NCT06649851 · Massachusetts General Hospital
2025-04-02 – 2030-01-31 · MGMT-Methylated Glioblastoma, Glioblastoma (GBM), Newly Diagnosed Glioblastoma Multiforme
What this study did
NCT01777919 · Olympion Medical Center
2027-01 – 2030-01 · Glioblastoma Multiforme
What this study did
NCT07476794 · Sunnybrook Health Sciences Centre
2025-11-01 – 2029-11 · Glioblastoma
What this study did
NCT07758062 · Tianjin Medical University General Hospital
2026-09-01 – 2029-09-01 · Glioblastoma
What this study did
NCT07439172 · The Cooper Health System
2026-07-13 – 2029-09 · High Grade Gliomas, Glioblastoma, Astrocytoma, Oligodendroglioma
What this study did
NCT07754734 · Dongguan People's Hospital
2026-08-10 – 2029-07-31 · Glioma, Glioblastoma (GBM), MGMT-Methylated Glioblastoma
What this study did
NCT07347210 · Centre Hospitalier Universitaire de Besancon
2026-01 – 2029-07 · Primary Glioblastoma
What this study did
NCT07297212 · BioNTech SE
2026-01-15 – 2029-07 · Recurrent Glioblastoma
What this study did
NCT07707973 · Tianjin First Central Hospital
2026-07-03 – 2029-06-03 · Glioma, Malignant
What this study did
NCT07326566 · Black Diamond Therapeutics, Inc.
2026-05-05 – 2029-03 · Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer
What this study did
NCT02344355 · Bryan Allen
2017-03-13 – 2028-12-31 · Glioblastoma Multiforme
What this study did
NCT07365280 · ZSky Biotech Inc
2026-01-09 – 2028-12-24 · Glioblastoma
What this study did
NCT07225621 · Alpheus Medical, Inc.
2026-01-28 – 2028-12 · Glioblastoma, GBM
What this study did
NCT03197506 · Mayo Clinic
2018-01-15 – 2028-06-06 · Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
What this study did
NCT04945148 · Hopital Foch
2024-05-10 – 2028-05 · Glioblastoma, IDH-wildtype
What this study did
NCT07193654 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-04-01 – 2028-04-01 · Glioblastoma (GBM)
What this study did
NCT06297512 · Iacopo Sardi
2022-12-09 – 2028-03-09 · Glioblastoma
What this study did
NCT06780592 · Huashan Hospital
2025-01-13 – 2027-12-31 · Glioblastoma
What this study did
NCT04049669 · Theodore S. Johnson
2019-10-02 – 2027-12-11 · Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
What this study did
NCT07670026 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-12-01 – 2027-12-01 · Glioblastoma
What this study did
NCT03405792 · University of Florida
2018-02-23 – 2027-12 · Glioblastoma, Glioblastoma, WHO Grade IV
What this study did
NCT04574856 · University of Michigan Rogel Cancer Center
2020-11-04 – 2027-11-19 · Glioblastoma
What this study did
NCT05629702 · University of Birmingham
2023-02-03 – 2027-10-07 · Glioblastoma, Brain Tumor, Cannabis, Brain Tumor, Recurrent
What this study did
NCT03862430 · NuvOx LLC
2023-03-31 – 2027-09-30 · Glioblastoma Multiforme
What this study did
NCT04116411 · Cecilia Soderberg-Naucler
2019-09-04 – 2027-09-16 · Glioblastoma Multiforme
What this study did
NCT04747145 · Medical College of Wisconsin
2021-06-03 – 2027-09 · Glioblastoma
What this study did
NCT03581292 · Children's Oncology Group
2018-11-06 – 2027-08-20 · Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
What this study did
NCT03688178 · Annick Desjardins, MD
2020-08-26 – 2027-03-31 · Glioblastoma
What this study did
NCT05463848 · L. Nicolas Gonzalez Castro, MD, PhD
2022-10-21 – 2027-03-01 · Glioblastoma, Recurrent Glioblastoma
What this study did
NCT05052957 · Leland Metheny
2023-01-20 – 2027-03-01 · Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma, Supratentorial Gliosarcoma
What this study did
NCT04623931 · M.D. Anderson Cancer Center
2020-01-30 – 2026-12-31 · Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, IDH-Wildtype, Glioblastoma, Oligoastrocytoma, Oligodendroglioma, WHO Grade II Glioma, WHO Grade III Glioma
What this study did
NCT06595186 · JenKem Technology Co., Ltd.
2022-10-31 – 2026-12-16 · Glioblastoma Multiforme (GBM)
What this study did
NCT02455557 · Roswell Park Cancer Institute
2015-05-04 – 2026-12-02 · Glioblastoma, Gliosarcoma
What this study did
NCT06353360 · Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
2024-04-30 – 2026-03-09 · Glioblastoma Multiforme
What this study did
NCT04267978 · Beijing Sanbo Brain Hospital
2020-02-13 – 2025-12-31 · Glioblastoma, Recurrent, Lower Grade Glioma, Recurrent
What this study did
NCT04523688 · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
2021-03-25 – 2025-12 · Glioblastoma, Vaccination
What this study did
NCT04388475 · Oblato, Inc.
2020-06-12 – 2025-03-05 · Recurrent Malignant Glioma, Brain Glioblastoma
What this study did
NCT05694416 · Zhongnan Hospital
2023-02-01 – 2025-03-01 · MGMT-Unmethylated Glioblastoma
What this study did
NCT04280848 · Centre Hospitalier Universitaire de Besancon
2020-05-26 – 2024-12-31 · Glioblastoma
What this study did
NCT05638451 · Zhujiang Hospital
2023-05-01 – 2024-12-30 · Recurrent Glioblastoma
What this study did
NCT04157478 · People's Hospital of Guangxi Zhuang Autonomous Region
2020-01 – 2024-12 · Glioblastoma
What this study did
NCT03137888 · Emory University
2017-09-20 – 2024-09-09 · Glioblastoma, Gliosarcoma
What this study did
NCT03650257 · Cure&Sure Biotech Co., LTD
2019-08-21 – 2024-08-20 · Glioma of Brain
What this study did
Phase 1/2 (151)
Glioblastoma
NCT06504381 · University of California, San Francisco
2025-01-08 – 2042-01-31 · High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma
What this study did
NCT07389278 · Sabine Mueller, MD, PhD
2027-06-01 – 2035-06-30 · Glioblastoma, High-Grade Glioma (WHO III-IV), High-grade Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Hemispheric Glioma, H3G34 Mutant
What this study did
NCT07811297 · Advenchen Pharmaceuticals, LLC.
2026-09-01 – 2031-09-01 · Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
What this study did
NCT07859059 · University of Nebraska
2027-06-01 – 2031-06-01 · High Grade Glioma, Glioblastoma, Gliosarcoma
What this study did
NCT04373785 · NeuGATE Theranostics
2027-01-01 – 2030-12-31 · Glioblastoma Multiforme
What this study did
NCT07569042 · Novelwise Pharmaceutical Corporation
2026-04-20 – 2030-12-31 · Malignant Neoplasm of Brain
What this study did
NCT06630260 · Institute of Cancer Research, United Kingdom
2024-11-15 – 2030-09-30 · Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Malignant Primary Gliomas
What this study did
NCT06012695 · Novelwise Pharmaceutical Corporation
2023-08-11 – 2029-09-30 · Malignant Neoplasm, Malignant Neoplasm of Brain
What this study did
NCT07391215 · Institute of Cancer Research, United Kingdom
2026-01-19 – 2029-06-30 · Malignant Primary Gliomas, Glioblastoma Multiforme (GBM)
What this study did
NCT03213002 · Northwell Health
2018-03-25 – 2029-06 · Glioblastoma Multiforme (GBM), Glioblastoma, Glioma of Brain, Glioblastoma, Adult, Brain Tumor, Brain Tumor, Primary, Brain Tumor Adult, Cancer, Brain Cancer
What this study did
NCT03491683 · Inovio Pharmaceuticals
2018-05-31 – 2027-12-31 · Glioblastoma
What this study did
NCT01837862 · Julie Krystal
2013-10-22 – 2027-12 · Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic, Optic Nerve Glioma, Pleomorphic Xanthoastrocytoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma, Diffuse Intrinsic Pontine Glioma, DIPG, Low-grade Glioma, Brainstem Glioma
What this study did
NCT06258018 · Armando Santoro, MD
2024-09 – 2027-09 · Glioma, Malignant
What this study did
NCT04019262 · John Flickinger
2021-12-14 – 2027-07 · Glioblastoma
What this study did
NCT02649582 · University Hospital, Antwerp
2015-12 – 2027-07 · Glioblastoma Multiforme of Brain
What this study did
NCT04881032 · Centre Jean Perrin
2022-03-07 – 2027-03 · Glioblastoma
What this study did
NCT03643549 · Haukeland University Hospital
2018-08-30 – 2026-12-31 · Glioblastoma
What this study did
NCT04443010 · Philogen S.p.A.
2021-01-20 – 2026-12 · Glioblastoma
What this study did
NCT05664464 · University of Zurich
2023-01-01 – 2026-12 · Glioblastoma
What this study did
NCT04478279 · Sapience Therapeutics
2020-07-01 – 2026-12 · Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
What this study did
NCT04910022 · Nerviano Medical Sciences
2021-12-01 – 2026-05-06 · Glioblastoma, Diffuse Glioma
What this study did
NCT03529448 · Grupo Español de Investigación en Neurooncología
2023-08-18 – 2025-11-13 · Glioblastoma
What this study did
NCT03174197 · M.D. Anderson Cancer Center
2017-06-30 – 2025-09-17 · Glioblastoma, Gliosarcoma
What this study did
NCT01985087 · University of Louisville
2014-09 – 2025-05 · Glioblastoma
What this study did
NCT06186440 · Zhongnan Hospital
2024-01-01 – 2025-01-01 · Glioblastoma Multiforme of Brain
What this study did
NCT02655601 · BioMimetix JV, LLC
2018-09-25 – 2024-12-31 · High Grade Glioma, Astrocytoma, Grade III, Glioblastoma
What this study did
NCT05663125 · Beijing Tiantan Hospital
2022-12-01 – 2024-12-30 · Recurrent Glioblastoma
What this study did
NCT02715609 · Washington University School of Medicine
2016-06-15 – 2024-05-12 · Glioblastoma Multiforme
What this study did
NCT04388033 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2020-12 – 2023-12 · Glioblastoma, Glioma, Neoplasms, Neuroepithelial, Neuroectodermal Tumors, Neoplasms, Neoplasms, Nerve Tissue, Vaccines, Immunologic Factors
What this study did
NCT03466450 · Grupo Español de Investigación en Neurooncología
2018-03-15 – 2023-11-29 · Glioblastoma
What this study did
NCT03914742 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2020-02-16 – 2023-10-31 · IDH1 Mutation, IDH2 Mutation, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
What this study did
NCT03782415 · MediciNova
2018-12-29 – 2023-08-07 · Glioblastoma, Recurrent Glioblastoma, GBM, Newly Diagnosed Glioblastoma
What this study did
NCT04421378 · Karyopharm Therapeutics Inc
2020-06-08 – 2023-07-03 · Glioblastoma Multiforme
What this study did
NCT04065087 · Genexine, Inc.
2019-08-22 – 2022-08-27 · Newly Diagnosed Glioblastoma
What this study did
NCT04119674 · Zhejiang Cancer Hospital
2019-03-19 – 2022-08-23 · Glioblastoma
What this study did
NCT01062399 · Radiation Therapy Oncology Group
2010-12 – 2022-05-20 · Brain and Central Nervous System Tumors
What this study did
NCT02661282 · M.D. Anderson Cancer Center
2016-06-01 – 2022-02-23 · Cytomegalovirus Positive, Glioblastoma, Gliosarcoma, Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Glioblastoma
What this study did
NCT03119064 · Brown University
2017-11-30 – 2021-10-08 · Glioblastoma Multiforme, Glioblastoma, GBM
What this study did
NCT00669669 · Fred Hutchinson Cancer Center
2009-02-25 – 2021-01-20 · Glioblastoma, Gliosarcoma
What this study did
NCT01120639 · Stanford University
2010-04 – 2020-11-15 · Glioblastoma, Cancer of Brain and Nervous System, Glioblastoma Multiforme
What this study did
NCT02590263 · AbbVie
2015-08-24 – 2020-08-27 · Malignant Glioma, Glioblastoma Multiforme
What this study did
NCT01790503 · Daiichi Sankyo
2013-07-18 – 2020-03-04 · Patients With Newly Diagnosed Glioblastoma
What this study did
NCT00555399 · M.D. Anderson Cancer Center
2007-11-28 – 2020-01-24 · Glioblastoma Multiforme, Anaplastic Glioma
What this study did
NCT00553150 · Alliance for Clinical Trials in Oncology
2009-03 – 2019-11-15 · Brain and Central Nervous System Tumors
What this study did
NCT00731731 · National Cancer Institute (NCI)
2009-07-10 – 2019-11-01 · Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
What this study did
NCT02364206 · Centre Jean Perrin
2015-06-08 – 2019-08 · Adult Glioblastoma
What this study did
Phase 1 (229)
Glioblastoma
NCT06410248 · Northwestern University
2024-07-23 – 2030-08-31 · Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
What this study did
NCT06831526 · Washington University School of Medicine
2025-11-06 – 2030-08-31 · Glioblastoma
What this study did
NCT05106296 · Theodore S. Johnson
2022-02-08 – 2029-12-28 · Ependymoma, Medulloblastoma, Glioblastoma, Primary Brain Tumor
What this study did
NCT03749187 · University of California, San Francisco
2019-04-03 – 2029-07-30 · Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
What this study did
NCT07457307 · NYU Langone Health
2026-06 – 2029-06 · High-grade Glioma
What this study did
NCT05236036 · Northwestern University
2022-08-08 – 2029-01-03 · Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
What this study did
NCT05083754 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2022-08-31 – 2029-01 · Glioblastoma Multiforme
What this study did
NCT06934889 · Memorial Sloan Kettering Cancer Center
2025-04-07 – 2028-04 · Glioblastoma, Gliosarcoma
What this study did
NCT02287428 · Dana-Farber Cancer Institute
2014-11 – 2028-02 · Glioblastoma
What this study did
NCT04555577 · M.D. Anderson Cancer Center
2020-09-20 – 2027-12-31 · Glioblastoma, Gliosarcoma
What this study did
NCT06072586 · St. Joseph's Hospital and Medical Center, Phoenix
2023-10-18 – 2027-12 · High Grade Glioma, Glioblastoma
What this study did
NCT04477200 · University of Michigan Rogel Cancer Center
2020-08-05 – 2027-11-05 · Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma, Newly Diagnosed Gliosarcoma, Newly Diagnosed Astrocytoma, Grade IV
What this study did
NCT07223034 · Memorial Sloan Kettering Cancer Center
2025-10-27 – 2027-10 · Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype, Diffuse Midline Glioma, H3 K27-Altered, Diffuse Hemispheric Glioma, H3 G34-mutant, Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype
What this study did
NCT05739942 · Novartis Pharmaceuticals
2024-05-15 – 2027-08-10 · Newly Diagnosed and Recurrent Glioblastoma
What this study did
NCT05698524 · University of Nebraska
2023-06-26 – 2027-07 · Recurrent High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma
What this study did
NCT04047706 · Northwestern University
2019-08-13 – 2027-06-01 · Glioblastoma
What this study did
NCT05109728 · Novartis Pharmaceuticals
2022-05-10 – 2027-05-24 · Glioblastoma
What this study did
NCT00268385 · National Cancer Institute (NCI)
2005-12-16 – 2027-04-24 · Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
What this study did
NCT05769660 · BeyondBio Inc.
2022-11-29 – 2026-12-31 · Glioblastoma Multiforme
What this study did
NCT04900792 · Bryan Allen
2023-02-28 – 2026-12-31 · Glioblastoma, Glioblastoma Multiforme
What this study did
NCT03587038 · University of Oklahoma
2018-09-03 – 2026-12-31 · Glioblastoma
What this study did
NCT04216329 · National Cancer Institute (NCI)
2020-07-07 – 2026-07-09 · Gliosarcoma, Newly Diagnosed, Glioblastoma
What this study did
NCT05879367 · Orbus Therapeutics, Inc.
2023-07-24 – 2026-06-30 · Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM, Astrocytoma, Astrocytoma, IDH-Mutant
What this study did
NCT07635173 · Shenzhen Zhenxing Medical Technology Co., Ltd
2022-09-19 – 2026-03-28 · Glioma, Glioblastomas (GBM), High Grade Gliomas
What this study did
NCT06095375 · Istituto Oncologico Veneto IRCCS
2022-07-04 – 2025-12-22 · Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma
What this study did
NCT00102648 · M.D. Anderson Cancer Center
2004-12-21 – 2025-12-01 · Malignant Supratentorial Neoplasm, Recurrent Glioblastoma, Recurrent Gliosarcoma
What this study did
NCT04968366 · Beijing Tiantan Hospital
2021-07-30 – 2025-10-31 · Glioblastoma Multiforme of Brain
What this study did
NCT04474353 · Stanford University
2021-05-21 – 2025-09-02 · Glioblastoma, Newly Diagnosed Glioblastoma
What this study did
NCT04614909 · Nader Sanai
2021-01-11 – 2025-05-28 · Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult
What this study did
NCT01430351 · M.D. Anderson Cancer Center
2011-09-14 – 2025-02-02 · Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
What this study did
NCT05700955 · University of Louisville
2022-11-01 – 2025-01 · Glioblastoma
What this study did
NCT01849146 · National Cancer Institute (NCI)
2013-10-24 – 2024-10-30 · Glioblastoma, Recurrent Glioblastoma
What this study did
NCT04842513 · University Hospital Tuebingen
2021-05-03 – 2024-07-31 · Glioblastoma Multiforme of Brain
What this study did
NCT05190315 · Mohammed Milhem
2022-01-28 – 2024-07-28 · Glioblastoma Multiforme
What this study did
NCT04324840 · Celgene
2020-07-10 – 2024-07-09 · Glioblastoma
What this study did
NCT04397679 · Barbara Ann Karmanos Cancer Institute
2021-08-12 – 2024-05-14 · Glioblastoma, Gliosarcoma
What this study did
NCT03451799 · Jethro Hu
2018-04-13 – 2024-04-29 · GBM, Glioblastoma
What this study did
NCT04200066 · University of Rochester
2022-06-01 – 2024-02-01 · Glioblastoma, Brain Tumor
What this study did
NCT03477110 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2018-05-04 – 2024-01-26 · Glioblastoma
What this study did
NCT03480867 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2017-03 – 2023-11 · Glioblastoma Multiforme, Adult
What this study did
NCT03426891 · H. Lee Moffitt Cancer Center and Research Institute
2018-03-16 – 2023-06-28 · Glioblastoma, Brain Tumor, GBM
What this study did
NCT03535350 · Case Comprehensive Cancer Center
2018-08-24 – 2023-04-04 · Glioblastoma
What this study did
NCT02311920 · National Cancer Institute (NCI)
2015-04-16 – 2022-12-22 · Gliosarcoma, Supratentorial Glioblastoma
What this study did
NCT03232424 · Hackensack Meridian Health
2017-07-26 – 2022-12-07 · Glioblastoma, Adult
What this study did
NCT04091503 · Center Trials & Treatment Europe
2019-12-20 – 2022-10-28 · Glioma, Malignant, Gliosarcoma, Astrocytoma of Brain
What this study did
NCT01269424 · Stanton Gerson MD
2011-11-22 – 2022-09-26 · Glioblastoma Multiforme
What this study did
NCT03463733 · M.E. van Linde
2018-03-02 – 2022-06-01 · Glioma, Glioblastoma
What this study did
NCT03224104 · European Organisation for Research and Treatment of Cancer - EORTC
2018-06-12 – 2022-05-05 · Astrocytoma, Grade III, Glioblastoma
What this study did
NCT03705351 · Providence Health & Services
2019-12-02 – 2022-02-24 · Glioblastoma, Cancer of Brain, Glioblastoma Multiforme, Brain Tumor
What this study did
Phase 4 (4)
Glioblastoma
NCT06625047 · Mayo Clinic
2024-10-07 – 2025-11-12 · Astrocytoma, IDH-Mutant, Glioblastoma, Glioma, Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted
What this study did
NCT00686725 · Merck Sharp & Dohme LLC
2008-06-24 – 2011-09-28 · Glioblastoma
What this study did
Glioma
NCT02496988 · The First People's Hospital of Changzhou
2015-07 – 2030-07 · Cytokine-Induced Killer Cells, Advanced Milignant Gliomas
What this study did
Other / comorbidity
NCT02343081 · Monte Verde SA
2012-01 – 2013-10 · Brain Neoplasms, Malignant, Primary
What this study did
Early phase / not applicable (28)
Glioblastoma
NCT06850766 · Ottawa Hospital Research Institute
2025-05-08 – 2031-11 · IDH-Wildtype Glioblastoma, Glioblastoma (GBM)
What this study did
NCT07894549 · Sun Yat-sen University
2026-10 – 2030-12 · Newly Diagnosed Glioblastoma, MGMT-Unmethylated Glioblastoma
What this study did
NCT06964815 · Istituto Oncologico Veneto IRCCS
2025-11-12 – 2027-10 · Glioblastoma, IDH Wild-type and STAT3-positive Glioblastoma
What this study did
NCT03181477 · Centre Georges Francois Leclerc
2017-04-07 – 2025-09-02 · Glioblastoma, Adult
What this study did
NCT03869242 · Tel-Aviv Sourasky Medical Center
2018-10-01 – 2021-12-01 · Glioblastoma
What this study did
NCT01987830 · Massachusetts General Hospital
2013-11 – 2019-04 · Recurrent Glioblastoma
What this study did
NCT03780569 · NovoCure Ltd.
2017-04-27 – 2019-01 · Glioblastoma Multiforme
What this study did
NCT01478854 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2011-12-27 – 2018-04-25 · Glioblastoma Multiforme
What this study did
NCT02039778 · Beth Israel Medical Center
2013-12 – 2015-12 · Glioblastoma, Malignant Glioma, Brain Tumors, Anaplastic Astrocytoma
What this study did
NCT01702610 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2008-12 – 2014-12 · Glioblastoma Mutliforme
What this study did
NCT01342757 · National Cancer Institute (NCI)
2010-12 – 2012-05 · Adult Glioblastoma, Depression, Recurrent Adult Brain Tumor
What this study did
NCT00756106 · Massachusetts General Hospital
2008-07 – 2012-02 · Brain and Central Nervous System Tumors
What this study did
Glioma
NCT07847476 · Assiut University
2026-10-01 – 2028-12-01 · Glioma Patients
What this study did
NCT03257618 · Institut du Cancer de Montpellier - Val d'Aurelle
2017-07-27 – 2021-12-31 · Glioma
What this study did
NCT03168919 · University of Alabama at Birmingham
2016-10-06 – 2018-06-12 · Glioma
What this study did
NCT02416999 · Hebei Yanda Hospital
2015-05 – 2018-05 · Recurrent High-grade Glioma
What this study did
NCT03082846 · Xue Xiaoying
2014-01-01 – 2016-12-03 · Glioma, Radiotherapy, Intensity-Modulated, Maximum Tolerated Dose
What this study did
NCT02082119 · Istituto Clinico Humanitas
2013-07 – 2016-05 · Glioma
What this study did
NCT00077207 · Children's Oncology Group
2004-07 – 2013-12 · Brain Tumor, Central Nervous System Tumor
What this study did
NCT00253487 · Children's Hospital Medical Center, Cincinnati
2005-08 – 2012-08 · Brain and Central Nervous System Tumors
What this study did
Other / comorbidity
NCT04199026 · M.D. Anderson Cancer Center
2025-02-25 – 2028-12-31 · Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
What this study did
NCT06832267 · Zhejiang Cancer Hospital
2025-02-14 – 2028-02-13 · Primary Central Nervous System Lymphoma
What this study did
NCT06553781 · Fudan University
2024-09-01 – 2027-09-01 · Malignant Melanoma
What this study did
NCT05204524 · Chinese Academy of Medical Sciences
2021-08-27 – 2023-08-27 · Leiomyosarcoma
What this study did
NCT02015728 · Seattle Children's Hospital
2013-12 – 2017-12 · Recurrent Childhood Brain Tumor
What this study did
NCT00416819 · University of California, San Francisco
2003-09 – 2012-02 · Brain and Central Nervous System Tumors, Lymphoma
What this study did
NCT00109798 · The Methodist Hospital Research Institute
2005-03 – 2006-07 · Central Nervous System Tumors, Lymphoma
What this study did
Used as active comparator (43)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (17)
Glioblastoma
NCT05902169 · CarThera
2024-01-29 – 2028-06-30 · Glioblastoma, Recurrent Glioblastoma, GBM
What this study did
NCT06388733 · Ivy Brain Tumor Center
2024-06-19 – 2028-03 · Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor
What this study did
NCT03149575 · DelMar Pharmaceuticals, Inc.
2017-10-27 – 2019-08-31 · Glioblastoma Multiforme, Glioblastoma, Glioma, GBM, Brain Cancer
What this study did
NCT00916409 · NovoCure Ltd.
2009-06 – 2017-03 · Glioblastoma Multiforme
What this study did
NCT00761280 · Isarna Therapeutics GmbH
2008-12 – 2012-06 · Anaplastic Astrocytoma, Glioblastoma
What this study did
Glioma
NCT07004075 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
2025-06-30 – 2029-04-30 · Low-grade Glioma, Pediatric Low-grade Gliomas, pLGG With BRAF Alteration
What this study did
NCT01260103 · Burzynski Research Institute
2011-12 – 2018-12 · Optic Nerve Glioma
What this study did
Other / comorbidity
NCT06743126 · Immatics US, Inc.
2025-01-14 – 2032-08-12 · Melanoma, Cutaneous Malignant, Mucosal Melanoma
What this study did
NCT07104032 · Ono Pharmaceutical Co., Ltd.
2026-06-12 – 2029-12 · Relapsed/Refractory Primary Central Nervous System Lymphoma
What this study did
NCT06346067 · Erasca, Inc.
2024-04-29 – 2028-12 · Advanced or Metastatic NRAS-mutant Melanoma
What this study did
NCT06008106 · Shanghai Kechow Pharma, Inc.
2023-11-02 – 2027-09-22 · Melanoma
What this study did
NCT04919226 · ITM Solucin GmbH
2021-12-21 – 2027-09 · Neuroendocrine Tumors
What this study did
NCT05647954 · Taizhou Hanzhong biomedical co. LTD
2022-12-31 – 2025-06-30 · Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms
What this study did
NCT02288897 · Provectus Biopharmaceuticals, Inc.
2015-04 – 2019-09 · Cutaneous Melanoma
What this study did
NCT00395070 · Vical
2006-10 – 2013-07 · Metastatic Melanoma
What this study did
NCT00257205 · AstraZeneca
2006-03 – 2010-08 · Melanoma
What this study did
Phase 2/3 (6)
Glioblastoma
NCT03970447 · Global Coalition for Adaptive Research
2019-07-30 – 2030-06 · Glioblastoma
What this study did
NCT06105619 · Beijing Pearl Biotechnology Limited Liability Company
2018-10-08 – 2026-12-31 · Glioblastoma
What this study did
NCT03548571 · Oslo University Hospital
2018-04-26 – 2026-05-01 · Glioblastoma
What this study did
NCT04396860 · National Cancer Institute (NCI)
2020-09-01 – 2025-12-23 · Gliosarcoma, MGMT-Unmethylated Glioblastoma
What this study did
NCT02414165 · Tocagen Inc.
2015-11-30 – 2019-12-20 · Glioblastoma Multiforme, Anaplastic Astrocytoma
What this study did
Other / comorbidity
NCT06624644 · Linnaeus Therapeutics, Inc.
2025-08-06 – 2031-02 · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma
What this study did
Phase 2 (15)
Glioblastoma
NCT02977780 · David Reardon, MD
2017-02-09 – 2028-04-30 · Glioblastoma
What this study did
NCT01402063 · Brown University
2011-09 – 2015-06 · Glioblastoma Multiforme
What this study did
NCT00967330 · Hoffmann-La Roche
2010-06 – 2014-09 · Glioblastoma Multiforme
What this study did
NCT01285414 · Myrexis Inc.
2010-12 – 2012-03 · Glioblastoma Multiforme
What this study did
NCT00431561 · Isarna Therapeutics GmbH
2003-04 – 2009-03 · Glioblastoma, Anaplastic Astrocytoma
What this study did
Glioma
NCT06999148 · Yingjuan Zheng
2024-10-01 – 2028-05-01 · Glioma (Any Grade) in the Brain
What this study did
Other / comorbidity
NCT07310784 · Suzhou BlueHorse Therapeutics Co., Ltd.
2025-12-16 – 2028-12-31 · Advanced Melanoma
What this study did
NCT06703398 · Shanghai Juncell Therapeutics
2024-12-20 – 2027-12-20 · Melanoma
What this study did
NCT06514313 · Yizhuo Zhang
2024-07-03 – 2026-12-01 · Soft Tissue Sarcoma
What this study did
NCT02308527 · University of Birmingham
2013-07 – 2026-02-18 · Neuroblastoma
What this study did
NCT04462965 · Peking University Cancer Hospital & Institute
2020-05-30 – 2025-06-30 · Mucosal Melanoma
What this study did
NCT02836028 · Pfizer
2016-10 – 2020-06 · Ovarian Cancer
What this study did
NCT00338130 · AstraZeneca
2006-07 – 2013-07 · Melanoma
What this study did
NCT00991250 · SentoClone AB
2009-10 – 2011-09 · Malignant Melanoma
What this study did
Phase 1/2 (4)
Glioblastoma
NCT04121455 · TME Pharma AG
2019-09-12 – 2028-12 · Glioblastoma
What this study did
NCT03607643 · Leaf Vertical Inc.
2019-01-15 – 2020-12-15 · Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
What this study did
Other / comorbidity
NCT04625907 · University of Birmingham
2020-09-17 – 2030-06 · Rhabdomyosarcoma
What this study did
NCT01601184 · Centre Leon Berard
2012-06 – 2017-10 · Histologically Confirmed Medulloblastoma, Activation of the Sonic Hedgehog (SHH) Pathway
What this study did
Phase 1 (1)
Glioma
NCT05634707 · Duke University
2023-08-05 – 2027-06-05 · Primary Brain Tumor, Brain Tumor, Recurrent
What this study did
Appears in other studies (38)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (13)
Glioblastoma
NCT07452458 · NRG Oncology
2026-07-16 – 2035-07-15 · Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
What this study did
NCT06419946 · Vastra Gotaland Region
2025-02-01 – 2033-12-15 · Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma
What this study did
NCT06448286 · Jonsson Comprehensive Cancer Center
2026-12-01 – 2031-12-01 · Glioblastoma
What this study did
NCT07195591 · GT Medical Technologies, Inc.
2025-12-10 – 2031-12 · Glioblastoma
What this study did
NCT06556563 · NovoCure GmbH
2025-02-03 – 2029-04 · Glioblastoma
What this study did
NCT02685605 · Universitätsmedizin Mannheim
2016-12-09 – 2026-06 · Glioblastoma
What this study did
NCT02573324 · AbbVie
2015-01-04 – 2022-04-04 · Glioblastoma, Gliosarcoma
What this study did
NCT00943826 · Hoffmann-La Roche
2009-06-29 – 2015-09-09 · Glioblastoma
What this study did
NCT00884741 · National Cancer Institute (NCI)
2009-04-15 – 2013-03-17 · Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
What this study did
Glioma
NCT03763422 · European Organisation for Research and Treatment of Cancer - EORTC
2020-03-16 – 2021-12-29 · Low-grade Glioma, Temozolomide, Phase III, Wait or Treat
What this study did
Other / comorbidity
NCT07215910 · Alliance for Clinical Trials in Oncology
2026-06-24 – 2040-01 · Astrocytoma, IDH-Mutant, Grade 3
What this study did
NCT07940946 · Institut de Recherches Internationales Servier
2027-03-01 – 2034-11-01 · IDH-mutant High-grade Astrocytoma
What this study did
Phase 2/3 (1)
Glioblastoma
NCT07349693 · Everfront Biotech Co., Ltd.
2027-04-01 – 2029-12-31 · Recurrent Glioblastoma, IDH-Wildtype
What this study did
Phase 2 (18)
Glioblastoma
NCT07789379 · Wei Jiang
2026-10-01 – 2029-10-01 · Glioblastoma
What this study did
NCT05781321 · Mayo Clinic
2023-03-23 – 2028-11-30 · Glioblastoma
What this study did
NCT06218524 · Southern Medical University, China
2024-12-01 – 2028-07-31 · Glioblastoma Multiforme
What this study did
NCT02177578 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2014-07-08 – 2027-08 · Glioblastoma Multiforme
What this study did
NCT04485949 · Imvax
2023-03-20 – 2027-07 · Glioblastoma
What this study did
NCT04587830 · Polaris Group
2020-09-14 – 2027-05-30 · Glioblastoma Multiforme (GBM)
What this study did
Newly Diagnosed Glioblastomaactive not recruiting
NCT04959500 · Sun Yat-sen University
2021-07-21 – 2026-12-31 · Glioblastoma
What this study did
NCT04195139 · University of Sydney
2018-02-22 – 2025-12-31 · Glioblastoma Multiforme
What this study did
NCT04614493 · Assistance Publique - Hôpitaux de Paris
2021-09-11 – 2024-03 · Initial Radiological Diagnosis Eligible for Tumor Resection, Initial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type), Eligible for the Standard of Care Including Concurrent Temoradiation and Adjuvant Temozolomide
What this study did
NCT03018288 · National Cancer Institute (NCI)
2017-09-21 – 2022-12-20 · Glioblastoma
What this study did
NCT01062425 · National Cancer Institute (NCI)
2010-02-26 – 2022-05-20 · Adult Glioblastoma, Adult Gliosarcoma
What this study did
NCT00112502 · M.D. Anderson Cancer Center
2005-09 – 2014-09 · Brain and Central Nervous System Tumors, Glioblastoma Multiforme
What this study did
Glioma
NCT03180502 · NRG Oncology
2018-01-23 – 2031-07-13 · Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, Glioma, Oligoastrocytoma, Oligodendroglioma, WHO Grade 3 Glioma
What this study did
NCT04394858 · National Cancer Institute (NCI)
2021-03-17 – 2028-03-01 · Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma
What this study did
NCT06413706 · Eli Lilly and Company
2024-10-25 – 2028-02 · Glioma
What this study did
NCT03741244 · The Second Hospital of Hebei Medical University
2019-05-06 – 2023-02 · Glioma
What this study did
Other / comorbidity
NCT01638546 · National Cancer Institute (NCI)
2012-07-27 – 2027-03-25 · Recurrent Lung Small Cell Carcinoma
What this study did
Phase 1/2 (5)
Glioblastoma
NCT05432804 · National Cancer Institute (NCI)
2023-03-20 – 2027-06-30 · Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
What this study did
NCT04077866 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2023-06-01 – 2025-08-01 · Recurrent Glioblastoma, Refractory Glioblastoma
What this study did
NCT02942264 · National Cancer Institute (NCI)
2016-12-14 – 2020-08-26 · Brain Tumor, Astrocytoma, Astroglioma, Glioblastoma, Gliosarcoma
What this study did
NCT00869401 · Alliance for Clinical Trials in Oncology
2009-06 – 2019-11-15 · Brain and Central Nervous System Tumors
What this study did
NCT02085304 · St. Joseph's Hospital and Medical Center, Phoenix
2013-05-07 – 2018-05-29 · Glioblastoma
What this study did
Phase 1 (1)
Other / comorbidity
NCT05400603 · Emory University
2023-11-06 – 2026-12 · Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
What this study did

Competitive landscape

This drug's own stage for Glioblastoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Temozolomide: this drugApprovedSmall moleculeDNA alkylation (O6-guanine)not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NiraparibPhase 3Small moleculePARP1/2not yet gradedNo reviewed efficacy summary in this indication
TemferonPhase 1/2Gene therapy / editingInterferon-alpha2 (myeloid-specific expression), Interferon-alpha2 (IFN-alpha2) expression in myeloid cellsnot yet gradedNo reviewed efficacy summary in this indication
TNG456Phase 1/2Small moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication
ZedoresertibPhase 1/2Small moleculeWEE1 kinasenot yet gradedNo reviewed efficacy summary in this indication
AZD1390Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
RalometostatDiscontinuedSmall moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(165 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Temozolomide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (24)
November 2026 (3)
Phase 1/2GlioblastomaActive not recruiting
Est. primary completion 2026-11 · NCT04881032 · CT.gov ↗
What to watch
Phase 3High-Risk Neuroblastoma, Patient With Insufficient Response ChemoimmunotherapyRecruiting
Est. primary completion 2026-11 · NCT04221035 · CT.gov ↗
What to watch
Phase 1GlioblastomaRecruiting
Est. primary completion 2026-11-30 · NCT05769660 · CT.gov ↗
What to watch
December 2026 (21)
Phase 1GliomaActive not recruiting
Est. primary completion 2026-12 · NCT03011671 · CT.gov ↗
What to watch
Phase 1Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, MedulloblastomaActive not recruiting
Est. primary completion 2026-12 · NCT04337177 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaNot yet recruiting
Est. primary completion 2026-12 · NCT06258018 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaActive not recruiting
Est. primary completion 2026-12 · NCT04019262 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaActive not recruiting
Est. primary completion 2026-12 · NCT04478279 · CT.gov ↗
What to watch
Phase 1/2Relapsed Neuroblastoma, Refractory NeuroblastomaActive not recruiting
Est. primary completion 2026-12 · NCT04211675 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaActive not recruiting
Est. primary completion 2026-12 · NCT05664243 · CT.gov ↗
What to watch
Phase 2Neuroendocrine Carcinomas (NEC)Not yet recruiting
Est. primary completion 2026-12 · NCT07156019 · CT.gov ↗
What to watch
Phase 2Gastrointestinal Stromal TumorsRecruiting
Est. primary completion 2026-12-01 · NCT05661643 · CT.gov ↗
What to watch
Phase 3Neuroblastoma (NB), GanglioneuroblastomaRecruiting
Est. primary completion 2026-12-15 · NCT07375563 · CT.gov ↗
What to watch
Phase 1Lymphoma, Primary Central Nervous System LymphomaRecruiting
Est. primary completion 2026-12-30 · NCT06475235 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaRecruiting
Est. primary completion 2026-12-30 · NCT03643549 · CT.gov ↗
What to watch
Phase 1Refractory Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT06006273 · CT.gov ↗
What to watch
Phase 1/2GliomaRecruiting
Est. primary completion 2026-12-31 · NCT06703255 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2026-12-31 · NCT05983237 · CT.gov ↗
What to watch
Phase 1/2Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor …Recruiting
Est. primary completion 2026-12-31 · NCT04901702 · CT.gov ↗
What to watch
Phase 2Solid Tumor, Precision MedicineRecruiting
Est. primary completion 2026-12-31 · NCT06739395 · CT.gov ↗
What to watch
Phase 2NeuroblastomaRecruiting
Est. primary completion 2026-12-31 · NCT06013618 · CT.gov ↗
What to watch
Phase 2GlioblastomaRecruiting
Est. primary completion 2026-12-31 · NCT04623931 · CT.gov ↗
What to watch
Phase 3GliomaRecruiting
Est. primary completion 2026-12-31 · NCT06330337 · CT.gov ↗
What to watch
Phase 3GliomaActive not recruiting
Est. primary completion 2026-12-31 · NCT00978458 · CT.gov ↗
What to watch
2027 (52)
January 2027 (4)
Phase 1/2Solid Tumor, RhabdomyosarcomaActive not recruiting
Est. primary completion 2027-01 · NCT04796012 · CT.gov ↗
What to watch
Phase 2GliomaRecruiting
Est. primary completion 2027-01 · NCT05188508 · CT.gov ↗
What to watch
Phase 1/2Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-01-03 · NCT03830918 · CT.gov ↗
What to watch
Phase 2GlioblastomaRecruiting
Est. primary completion 2027-01-31 · NCT06649851 · CT.gov ↗
What to watch
February 2027 (3)
Phase 1GlioblastomaActive not recruiting
Est. primary completion 2027-02 · NCT02287428 · CT.gov ↗
What to watch
Early phase / not applicablePrimary Central Nervous System LymphomaRecruiting
Est. primary completion 2027-02-13 · NCT06832267 · CT.gov ↗
What to watch
Phase 1GlioblastomaActive not recruiting
Est. primary completion 2027-02-15 · NCT04047706 · CT.gov ↗
What to watch
March 2027 (5)
Phase 1/2GlioblastomaActive not recruiting
Est. primary completion 2027-03 · NCT01837862 · CT.gov ↗
What to watch
Phase 1/2Advanced Malignant Solid Neoplasm, Advanced Microsatellite Stable Colorectal Carcinoma, Hematopoietic and Lymphatic System Neoplasm …Active not recruiting
Est. primary completion 2027-03-01 · NCT05691491 · CT.gov ↗
What to watch
Phase 1GliomaRecruiting
Est. primary completion 2027-03-15 · NCT05030298 · CT.gov ↗
What to watch
Phase 2Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8 …Recruiting
Est. primary completion 2027-03-31 · NCT05040360 · CT.gov ↗
What to watch
Phase 2GlioblastomaActive not recruiting
Est. primary completion 2027-03-31 · NCT03688178 · CT.gov ↗
What to watch
April 2027 (4)
Phase 2Ewing SarcomaRecruiting
Est. primary completion 2027-04 · NCT06827717 · CT.gov ↗
What to watch
Phase 2GlioblastomaRecruiting
Est. primary completion 2027-04-01 · NCT07193654 · CT.gov ↗
What to watch
Phase 3GlioblastomaRecruiting
Est. primary completion 2027-04-01 · NCT05271240 · CT.gov ↗
What to watch
Phase 1/2Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma …Recruiting
Est. primary completion 2027-04-15 · NCT05588453 · CT.gov ↗
What to watch
May 2027 (4)
Phase 2Newly Diagnosed Ewing SarcomaActive not recruiting
Est. primary completion 2027-05 · NCT01864109 · CT.gov ↗
What to watch
Phase 2Neoplasms, Child, AdolescentRecruiting
Est. primary completion 2027-05 · NCT05999994 · CT.gov ↗
What to watch
Early phase / not applicableGlioblastomaRecruiting
Est. primary completion 2027-05 · NCT06850766 · CT.gov ↗
What to watch
Phase 2Ewing's SarcomaNot yet recruiting
Est. primary completion 2027-05-01 · NCT07092306 · CT.gov ↗
What to watch
June 2027 (3)
Phase 1Neuroblastoma (NB)Active not recruiting
Est. primary completion 2027-06 · NCT03189706 · CT.gov ↗
What to watch
Phase 3GlioblastomaActive not recruiting
Est. primary completion 2027-06 · NCT03663725 · CT.gov ↗
What to watch
Phase 2GlioblastomaActive not recruiting
Est. primary completion 2027-06-30 · NCT03862430 · CT.gov ↗
What to watch
July 2027 (3)
Phase 1GlioblastomaRecruiting
Est. primary completion 2027-07 · NCT05698524 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaActive not recruiting
Est. primary completion 2027-07 · NCT02649582 · CT.gov ↗
What to watch
Phase 1Neuroblastoma, Neuroblastoma Recurrent, Relapsed Neuroblastoma, Refractory NeuroblastomaRecruiting
Est. primary completion 2027-07-01 · NCT07027748 · CT.gov ↗
What to watch
August 2027 (2)
Phase 1Sarcoma, Desmoplastic Small Round Cell Tumor (DSRCT)Active not recruiting
Est. primary completion 2027-08 · NCT01189643 · CT.gov ↗
What to watch
Phase 1GlioblastomaActive not recruiting
Est. primary completion 2027-08-10 · NCT05739942 · CT.gov ↗
What to watch
September 2027 (4)
Phase 1GliomaRecruiting
Est. primary completion 2027-09-01 · NCT03122197 · CT.gov ↗
What to watch
Early phase / not applicableLymphoma CnsRecruiting
Est. primary completion 2027-09-02 · NCT07191431 · CT.gov ↗
What to watch
Phase 1/2Neuroendocrine TumorsRecruiting
Est. primary completion 2027-09-15 · NCT06038461 · CT.gov ↗
What to watch
Phase 2GlioblastomaActive not recruiting
Est. primary completion 2027-09-16 · NCT04116411 · CT.gov ↗
What to watch
October 2027 (7)
Phase 1GlioblastomaRecruiting
Est. primary completion 2027-10 · NCT07223034 · CT.gov ↗
What to watch
Phase 2GlioblastomaRecruiting
Est. primary completion 2027-10 · NCT07476794 · CT.gov ↗
What to watch
Phase 2Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity CancerActive not recruiting
Est. primary completion 2027-10 · NCT06617923 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine CarcinomaActive not recruiting
Est. primary completion 2027-10-01 · NCT05247905 · CT.gov ↗
What to watch
Phase 2Recurrent Extensive Stage Small Cell Lung Carcinoma, Refractory Extensive Stage Small Cell Lung CarcinomaActive not recruiting
Est. primary completion 2027-10-01 · NCT03672773 · CT.gov ↗
What to watch
Phase 2GlioblastomaActive not recruiting
Est. primary completion 2027-10-07 · NCT05629702 · CT.gov ↗
What to watch
Phase 1/2GliomaRecruiting
Est. primary completion 2027-10-10 · NCT07599371 · CT.gov ↗
What to watch
November 2027 (2)
Phase 1/2GliomaActive not recruiting
Est. primary completion 2027-11 · NCT06478212 · CT.gov ↗
What to watch
Phase 2GlioblastomaRecruiting
Est. primary completion 2027-11-09 · NCT06297512 · CT.gov ↗
What to watch
December 2027 (11)
Phase 1GlioblastomaRecruiting
Est. primary completion 2027-12 · NCT06072586 · CT.gov ↗
What to watch
Phase 2GlioblastomaRecruiting
Est. primary completion 2027-12 · NCT07225621 · CT.gov ↗
What to watch
Phase 2Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)Not yet recruiting
Est. primary completion 2027-12-01 · NCT07444918 · CT.gov ↗
What to watch
Phase 2GlioblastomaRecruiting
Est. primary completion 2027-12-01 · NCT07670026 · CT.gov ↗
What to watch
Phase 2Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Malignant Solid Neoplasm, Pancreatic Neuroendocrine NeoplasmNot yet recruiting
Est. primary completion 2027-12-15 · NCT06202066 · CT.gov ↗
What to watch
Phase 2Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma …Recruiting
Est. primary completion 2027-12-30 · NCT04919382 · CT.gov ↗
What to watch
Phase 1GlioblastomaActive not recruiting
Est. primary completion 2027-12-31 · NCT04555577 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaActive not recruiting
Est. primary completion 2027-12-31 · NCT03491683 · CT.gov ↗
What to watch
Phase 2Pan-tumorRecruiting
Est. primary completion 2027-12-31 · NCT04566380 · CT.gov ↗
What to watch
Phase 2Head and Neck Mucosal MelanomasNot yet recruiting
Est. primary completion 2027-12-31 · NCT07353073 · CT.gov ↗
What to watch
Phase 2GlioblastomaActive not recruiting
Est. primary completion 2027-12-31 · NCT02344355 · CT.gov ↗
What to watch
2028 (36)
January 2028 (6)
Phase 1GlioblastomaRecruiting
Est. primary completion 2028-01 · NCT05083754 · CT.gov ↗
What to watch
Phase 2GlioblastomaRecruiting
Est. primary completion 2028-01 · NCT07297212 · CT.gov ↗
What to watch
Phase 2GlioblastomaNot yet recruiting
Est. primary completion 2028-01-03 · NCT07707973 · CT.gov ↗
What to watch
Phase 2LymphomaRecruiting
Est. primary completion 2028-01-09 · NCT07015242 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaRecruiting
Est. primary completion 2028-01-31 · NCT06504381 · CT.gov ↗
What to watch
Phase 2Soft Tissue Sarcoma (Excluding GIST)Not yet recruiting
Est. primary completion 2028-01-31 · NCT07457775 · CT.gov ↗
What to watch
February 2028 (2)
Phase 2Neuroblastoma RecurrentRecruiting
Est. primary completion 2028-02-01 · NCT07085338 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid MalignanciesRecruiting
Est. primary completion 2028-02-07 · NCT05417594 · CT.gov ↗
What to watch
March 2028 (1)
Phase 1GlioblastomaRecruiting
Est. primary completion 2028-03-30 · NCT05106296 · CT.gov ↗
What to watch
April 2028 (2)
Phase 1GlioblastomaRecruiting
Est. primary completion 2028-04 · NCT06934889 · CT.gov ↗
What to watch
Phase 2Breast Cancer Triple NegativeNot yet recruiting
Est. primary completion 2028-04-01 · NCT05128734 · CT.gov ↗
What to watch
May 2028 (3)
Phase 1/2Wilms TumorRecruiting
Est. primary completion 2028-05 · NCT05384821 · CT.gov ↗
What to watch
Phase 2GlioblastomaRecruiting
Est. primary completion 2028-05 · NCT04945148 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaRecruiting
Est. primary completion 2028-05-30 · NCT06012695 · CT.gov ↗
What to watch
June 2028 (4)
Phase 1GlioblastomaNot yet recruiting
Est. primary completion 2028-06 · NCT07457307 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaRecruiting
Est. primary completion 2028-06 · NCT03213002 · CT.gov ↗
What to watch
Phase 1NeuroblastomaRecruiting
Est. primary completion 2028-06-01 · NCT06995872 · CT.gov ↗
What to watch
Phase 2GliomaRecruiting
Est. primary completion 2028-06-15 · NCT05096481 · CT.gov ↗
What to watch
July 2028 (3)
Phase 1/2GliomaNot yet recruiting
Est. primary completion 2028-07 · NCT02494804 · CT.gov ↗
What to watch
Phase 4GliomaNot yet recruiting
Est. primary completion 2028-07 · NCT02496988 · CT.gov ↗
What to watch
Phase 2Neuroendocrine Tumor Grade 2, Neuroendocrine TumorsRecruiting
Est. primary completion 2028-07-01 · NCT04339036 · CT.gov ↗
What to watch
August 2028 (2)
Phase 1/2Advanced Cancer, Metastatic Solid TumorRecruiting
Est. primary completion 2028-08 · NCT05004116 · CT.gov ↗
What to watch
Phase 2Solid TumorsRecruiting
Est. primary completion 2028-08-15 · NCT07492680 · CT.gov ↗
What to watch
September 2028 (3)
Phase 1/2GlioblastomaRecruiting
Est. primary completion 2028-09 · NCT05765812 · CT.gov ↗
What to watch
Phase 2GlioblastomaRecruiting
Est. primary completion 2028-09 · NCT07439172 · CT.gov ↗
What to watch
Phase 1GliomaRecruiting
Est. primary completion 2028-09-01 · NCT07025226 · CT.gov ↗
What to watch
October 2028 (1)
Early phase / not applicableGliomaNot yet recruiting
Est. primary completion 2028-10-01 · NCT07847476 · CT.gov ↗
What to watch
November 2028 (2)
Phase 2GlioblastomaRecruiting
Est. primary completion 2028-11 · NCT07326566 · CT.gov ↗
What to watch
Phase 1/2Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor, Refractory Sarcoma, Osteosarcoma, RhabdomyosarcomaRecruiting
Est. primary completion 2028-11-01 · NCT06709495 · CT.gov ↗
What to watch
December 2028 (7)
Phase 1Ewing Sarcoma, Colorectal AdenocarcinomaRecruiting
Est. primary completion 2028-12 · NCT03715933 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerActive not recruiting
Est. primary completion 2028-12 · NCT03351296 · CT.gov ↗
What to watch
Phase 2NeuroblastomaRecruiting
Est. primary completion 2028-12 · NCT06450041 · CT.gov ↗
What to watch
Phase 2GlioblastomaNot yet recruiting
Est. primary completion 2028-12-24 · NCT07365280 · CT.gov ↗
What to watch
Phase 2Neuroblastoma (NB), Neuroblastoma in ChildrenRecruiting
Est. primary completion 2028-12-31 · NCT07318831 · CT.gov ↗
What to watch
Phase 3GlioblastomaRecruiting
Est. primary completion 2028-12-31 · NCT05439278 · CT.gov ↗
What to watch
Early phase / not applicableMetastatic Sarcoma, Recurrent Sarcoma, Resectable SarcomaRecruiting
Est. primary completion 2028-12-31 · NCT04199026 · CT.gov ↗
What to watch
2029 (19)
January 2029 (4)
Phase 2GlioblastomaNot yet recruiting
Est. primary completion 2029-01 · NCT01777919 · CT.gov ↗
What to watch
Phase 2GlioblastomaNot yet recruiting
Est. primary completion 2029-01 · NCT07347210 · CT.gov ↗
What to watch
Phase 1GlioblastomaActive not recruiting
Est. primary completion 2029-01-03 · NCT05236036 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaRecruiting
Est. primary completion 2029-01-19 · NCT07391215 · CT.gov ↗
What to watch
April 2029 (1)
Phase 1GliomaRecruiting
Est. primary completion 2029-04-30 · NCT06428045 · CT.gov ↗
What to watch
July 2029 (2)
Phase 2High-risk Neuroblastoma, Neuroblastoma, Childhood NeuroblastomaRecruiting
Est. primary completion 2029-07-22 · NCT06528496 · CT.gov ↗
What to watch
Phase 2GlioblastomaNot yet recruiting
Est. primary completion 2029-07-31 · NCT07754734 · CT.gov ↗
What to watch
August 2029 (3)
Phase 2GlioblastomaNot yet recruiting
Est. primary completion 2029-08-01 · NCT07758062 · CT.gov ↗
What to watch
Phase 2CancerRecruiting
Est. primary completion 2029-08-25 · NCT03899155 · CT.gov ↗
What to watch
Phase 2GlioblastomaRecruiting
Est. primary completion 2029-08-31 · NCT05843253 · CT.gov ↗
What to watch
September 2029 (5)
Phase 2Melanoma (Skin Cancer)Not yet recruiting
Est. primary completion 2029-09-01 · NCT07501104 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaRecruiting
Est. primary completion 2029-09-30 · NCT06630260 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaRecruiting
Est. primary completion 2029-09-30 · NCT07569042 · CT.gov ↗
What to watch
Phase 2Mucosal Melanoma, PD-L1 PositiveRecruiting
Est. primary completion 2029-09-30 · NCT07400302 · CT.gov ↗
What to watch
Phase 2/3GlioblastomaNot yet recruiting
Est. primary completion 2029-09-30 · NCT07605364 · CT.gov ↗
What to watch
October 2029 (2)
Phase 1/2GliomaRecruiting
Est. primary completion 2029-10 · NCT07243470 · CT.gov ↗
What to watch
Phase 3GliomaActive not recruiting
Est. primary completion 2029-10-31 · NCT00887146 · CT.gov ↗
What to watch
December 2029 (2)
Phase 1/2Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung CancerRecruiting
Est. primary completion 2029-12-31 · NCT06681220 · CT.gov ↗
What to watch
Phase 3Ganglioneuroblastoma, Nodular, NeuroblastomaRecruiting
Est. primary completion 2029-12-31 · NCT06172296 · CT.gov ↗
What to watch
2030 (21)
January 2030 (1)
Phase 2Cutaneous MelanomaNot yet recruiting
Est. primary completion 2030-01-01 · NCT07807878 · CT.gov ↗
What to watch
March 2030 (2)
Phase 2GlioblastomaRecruiting
Est. primary completion 2030-03 · NCT06805305 · CT.gov ↗
What to watch
Early phase / not applicableGlioblastomaNot yet recruiting
Est. primary completion 2030-03 · NCT07894549 · CT.gov ↗
What to watch
April 2030 (2)
Phase 1/2Refractory Solid Tumors, Relapsed Solid Tumors, Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Rhabdomyosarcoma …Recruiting
Est. primary completion 2030-04 · NCT06721689 · CT.gov ↗
What to watch
Phase 2Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent, Rare CNS Tumor RecurrentRecruiting
Est. primary completion 2030-04 · NCT01356290 · CT.gov ↗
What to watch
June 2030 (2)
Phase 1/2GlioblastomaNot yet recruiting
Est. primary completion 2030-06-01 · NCT07859059 · CT.gov ↗
What to watch
Phase 1/2SCLC, Extensive StageNot yet recruiting
Est. primary completion 2030-06-30 · NCT07141771 · CT.gov ↗
What to watch
July 2030 (1)
Phase 1/2GlioblastomaNot yet recruiting
Est. primary completion 2030-07-30 · NCT04373785 · CT.gov ↗
What to watch
September 2030 (3)
Phase 1/2GlioblastomaNot yet recruiting
Est. primary completion 2030-09 · NCT07762716 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaNot yet recruiting
Est. primary completion 2030-09-01 · NCT07811297 · CT.gov ↗
What to watch
Phase 2Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, NosRecruiting
Est. primary completion 2030-09-30 · NCT06861244 · CT.gov ↗
What to watch
October 2030 (3)
Phase 1Metastatic Ewing SarcomaRecruiting
Est. primary completion 2030-10 · NCT07194044 · CT.gov ↗
What to watch
Phase 1Progressive Pediatric Brain CancerNot yet recruiting
Est. primary completion 2030-10-08 · NCT07732413 · CT.gov ↗
What to watch
Phase 2/3GlioblastomaNot yet recruiting
Est. primary completion 2030-10-15 · NCT07873996 · CT.gov ↗
What to watch
November 2030 (3)
Phase 1/2GliomaNot yet recruiting
Est. primary completion 2030-11 · NCT07562971 · CT.gov ↗
What to watch
Phase 2/3GlioblastomaActive not recruiting
Est. primary completion 2030-11 · NCT05685004 · CT.gov ↗
What to watch
Phase 1/2Neuroblastoma, Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, LiposarcomaRecruiting
Est. primary completion 2030-11-01 · NCT06541262 · CT.gov ↗
What to watch
December 2030 (4)
Phase 1/2Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Recurrent Cancer, Refractory CancerRecruiting
Est. primary completion 2030-12 · NCT06208657 · CT.gov ↗
What to watch
Phase 2GlioblastomaRecruiting
Est. primary completion 2030-12 · NCT06991101 · CT.gov ↗
What to watch
Phase 1CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor, Medulloblastoma, Childhood, Medulloblastoma, Group 3 …Recruiting
Est. primary completion 2030-12-31 · NCT06942039 · CT.gov ↗
What to watch
Phase 1/2Relapsed NeuroblastomaRecruiting
Est. primary completion 2030-12-31 · NCT07334301 · CT.gov ↗
What to watch
2031 (5)
February 2031 (1)
Phase 1/2Pediatric CancerRecruiting
Est. primary completion 2031-02 · NCT02813135 · CT.gov ↗
What to watch
March 2031 (2)
Phase 2/3High-Risk NeuroblastomaRecruiting
Est. primary completion 2031-03 · NCT07549321 · CT.gov ↗
What to watch
Phase 1/2Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma RecurrentRecruiting
Est. primary completion 2031-03-31 · NCT07346157 · CT.gov ↗
What to watch
October 2031 (1)
Phase 3Gastroenteropancreatic Neuroendocrine TumorsNot yet recruiting
Est. primary completion 2031-10-11 · NCT07910760 · CT.gov ↗
What to watch
November 2031 (1)
Phase 2NeuroblastomaRecruiting
Est. primary completion 2031-11-26 · NCT07932808 · CT.gov ↗
What to watch
2032 (3)
June 2032 (2)
Phase 2GlioblastomaActive not recruiting
Est. primary completion 2032-06 · NCT04765514 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaNot yet recruiting
Est. primary completion 2032-06-30 · NCT07389278 · CT.gov ↗
What to watch
December 2032 (1)
Phase 3GlioblastomaNot yet recruiting
Est. primary completion 2032-12-31 · NCT06477939 · CT.gov ↗
What to watch
2034 (2)
February 2034 (1)
Phase 2Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4Not yet recruiting
Est. primary completion 2034-02-01 · NCT07888647 · CT.gov ↗
What to watch
October 2034 (1)
Phase 2RhabdomyosarcomaRecruiting
Est. primary completion 2034-10 · NCT06023641 · CT.gov ↗
What to watch
2035 (2)
June 2035 (1)
Phase 3Pancreatic Neuroendocrine Tumors (pNET), Pancreatic Neuroendocrine TumorsNot yet recruiting
Est. primary completion 2035-06 · NCT07591493 · CT.gov ↗
What to watch
November 2035 (1)
Phase 3GlioblastomaRecruiting
Est. primary completion 2035-11-30 · NCT07935889 · CT.gov ↗
What to watch
2036 (1)
August 2036 (1)
Phase 2GlioblastomaRecruiting
Est. primary completion 2036-08-31 · NCT07708961 · CT.gov ↗
What to watch

See the full readout calendar ↗